Rosa Álvarez

3.4k total citations · 1 hit paper
94 papers, 1.9k citations indexed

About

Rosa Álvarez is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Rosa Álvarez has authored 94 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 34 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in Rosa Álvarez's work include Sarcoma Diagnosis and Treatment (22 papers), Lung Cancer Treatments and Mutations (16 papers) and HIV/AIDS drug development and treatment (12 papers). Rosa Álvarez is often cited by papers focused on Sarcoma Diagnosis and Treatment (22 papers), Lung Cancer Treatments and Mutations (16 papers) and HIV/AIDS drug development and treatment (12 papers). Rosa Álvarez collaborates with scholars based in Spain, Italy and Belgium. Rosa Álvarez's co-authors include Marı́a-José Camarasa, Erik De Clercq, Sonsoles Velázquez, Ana San‐Félix, Jan Balzarini, Anna Karlsson, Stefano Aquaro, Carlo Federico Perno, Jan Balzarini and Federico Gago and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Rosa Álvarez

86 papers receiving 1.9k citations

Hit Papers

1,2,3-Triazole-[2,5-Bis-O-(tert-butyldimethylsilyl)-.beta... 1994 2026 2004 2015 1994 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 1,2,3-Triazole-[2,5-Bis-O-(tert-butyldimethylsilyl)-.beta.-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) (TSAO) Analogs: Synthesis and Anti-HIV-1 Activity
    1994 700 citations Rosa Álvarez et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rosa Álvarez Spain 18 967 602 444 304 255 94 1.9k
Johan Harmenberg Sweden 24 209 0.2× 502 0.8× 472 1.1× 325 1.1× 234 0.9× 81 1.9k
Davide Genini United States 19 278 0.3× 799 1.3× 442 1.0× 47 0.2× 136 0.5× 24 1.7k
Takahiko Sakuma Japan 20 106 0.1× 504 0.8× 203 0.5× 220 0.7× 73 0.3× 64 1.2k
Mohammad Rashidian United States 26 445 0.5× 1.1k 1.8× 1.1k 2.5× 142 0.5× 227 0.9× 48 2.6k
Frank M. Schabel United States 17 196 0.2× 474 0.8× 350 0.8× 131 0.4× 148 0.6× 32 1.2k
Raymond T. Camphausen United States 21 381 0.4× 1.1k 1.8× 268 0.6× 69 0.2× 67 0.3× 27 2.3k
Manfred Hagedorn Germany 23 522 0.5× 490 0.8× 335 0.8× 52 0.2× 42 0.2× 111 1.9k
Nicole Benoit United States 19 78 0.1× 1.2k 1.9× 734 1.7× 291 1.0× 66 0.3× 30 2.2k
Christian Jöst Switzerland 18 156 0.2× 582 1.0× 352 0.8× 82 0.3× 42 0.2× 32 1.1k
Patricia K. Lumma United States 15 263 0.3× 439 0.7× 143 0.3× 70 0.2× 194 0.8× 20 959

Countries citing papers authored by Rosa Álvarez

Since Specialization
Citations

This map shows the geographic impact of Rosa Álvarez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosa Álvarez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosa Álvarez more than expected).

Fields of papers citing papers by Rosa Álvarez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosa Álvarez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosa Álvarez. The network helps show where Rosa Álvarez may publish in the future.

Co-authorship network of co-authors of Rosa Álvarez

This figure shows the co-authorship network connecting the top 25 collaborators of Rosa Álvarez. A scholar is included among the top collaborators of Rosa Álvarez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosa Álvarez. Rosa Álvarez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Isla, Dolores, Rosa Álvarez, María José Domper-Arnal, et al.. (2024). Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis. Journal of Medical Economics. 27(1). 1379–1387. 3 indexed citations
3.
Kim, Dong‐Wan, Byoung Chul Cho, Sang‐We Kim, et al.. (2024). Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study. Lung Cancer. 190. 107530–107530. 5 indexed citations
4.
Salazar, Juliana, María J. Arranz, Javier Martín‐Broto, et al.. (2024). Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol. Pharmaceutics. 16(12). 1585–1585. 1 indexed citations
5.
Martín‐Broto, Javier, Kateřina Kopečková, Ignacio Azinovic, et al.. (2023). 1926P Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study. Annals of Oncology. 34. S1035–S1036. 1 indexed citations
6.
7.
8.
Escudero‐Vilaplana, Vicente, et al.. (2022). Possible heart failure caused by osimertinib in a lung cancer patient. Journal of Oncology Pharmacy Practice. 29(4). 1015–1020. 4 indexed citations
9.
Majem, Margarita, et al.. (2022). Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain. SHILAP Revista de lepidopterología. 9. 82–90. 1 indexed citations
10.
Calles, Antonio, et al.. (2020). Impact of COVID-19 in continuity ofcancer treatment for lung cancer patients. Clinical Cancer Research. 26(18). 1 indexed citations
11.
Grobler, Jay A., Annaliesa S. Anderson, Prabhavathi Fernandes, et al.. (2020). Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics. Cell Host & Microbe. 28(5). 638–645. 25 indexed citations
12.
Paz‐Ares, Luis, David Vicente, Enriqueta Felip, et al.. (2020). 1272P Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S822–S822. 1 indexed citations
13.
Álvarez, Rosa, Antonio Calles, Carlos López, et al.. (2019). Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients. Clinical & Translational Oncology. 22(4). 555–562. 14 indexed citations
14.
Márquez‐Rodas, Iván, Federico Longo, María E. Rodríguez-Ruiz, et al.. (2018). Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. Annals of Oncology. 29. viii732–viii732. 7 indexed citations
15.
Calvo, Aitana, Sara López‐Tarruella, Rosa Álvarez, et al.. (2017). Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients. Annals of Oncology. 28. v135–v135.
16.
Álvarez, Rosa, et al.. (2015). Analgesia basada en infusión continua de anestésico local a nivel interfascial tras cirugía de colon laparoscópico: Ensayo clínico. Revista Española de Anestesiología y Reanimación. 63(4). 197–206. 5 indexed citations
17.
Álvarez, Rosa, et al.. (2015). An ultra-radical surgical approach for recurrent vulvar cancer involving en-bloc excision of the infra-renal aorta. International Journal of Gynecology & Obstetrics. 132(3). 353–354. 1 indexed citations
18.
Álvarez, Rosa, et al.. (2014). Actualización en el tratamiento de la osteoporosis: manejo desde una unidad del dolor (1.ª parte). Revista de la Sociedad Española del Dolor. 21(6). 328–337.
19.
Álvarez, Rosa. (2009). La investigación etnográfica: una propuesta metodológica para Trabajo Social. 74–97. 1 indexed citations
20.
Gómez, Susana, Ángel A. Juan, & Rosa Álvarez. (1970). Multiscale Optimization For Aquifer Parameter Identification With Noisy Data. WIT Transactions on Ecology and the Environment. 24. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johan Harmenberg Breakdown of academic impact, for papers by Davide Genini Breakdown of academic impact, for papers by Takahiko Sakuma Breakdown of academic impact, for papers by Mohammad Rashidian Breakdown of academic impact, for papers by Frank M. Schabel Breakdown of academic impact, for papers by Raymond T. Camphausen Breakdown of academic impact, for papers by Manfred Hagedorn Breakdown of academic impact, for papers by Nicole Benoit Breakdown of academic impact, for papers by Christian Jöst Breakdown of academic impact, for papers by Patricia K. Lumma
Rankless by CCL
2026